Death Caused by Disseminated Herpes Zoster in a Patient with Multiple Myeloma: A Case Report and Literature Review

References

• Shin BS, Na CH, Song IG, Choi KC. A case of human immunodeficiency virus infection initially presented with disseminated herpes zoster. Ann Dermatol. 2010;22(2):199–202. doi:10.5021/ad.2010.22.2.199
   PubMed Web of Science ®Google Scholar
• Valković T, Gačić V, Ivandić J, et al. Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors. Turk J Haematol. 2015;32(3):234–242. doi:10.4274/tjh.2013.0173
   PubMed Web of Science ®Google Scholar
• Shindo T, Kimura S. Immune defects in multiple myeloma. Nihon Rinsho. Japan J Clin Med. 2015;73(1):52–56.
   PubMedGoogle Scholar
• Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113. doi:10.3324/haematol.2014.107714
   PubMed Web of Science ®Google Scholar
• Tsai CK, Liu YC, Kuan AS, et al. Risk and impact of invasive fungal infections in patients with multiple myeloma. Ann Hematol. 2020;99(8):1813–1822. doi:10.1007/s00277-020-04125-z
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211–1225. doi:10.1086/605664
   PubMed Web of Science ®Google Scholar
• Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138(5):563–579. doi:10.1111/j.1365-2141.2007.06705.x
   PubMed Web of Science ®Google Scholar
• Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570–1582. doi:10.1080/10428190500472503
   PubMed Web of Science ®Google Scholar
• Ludwig H, Kumar S. Prevention of infections including vaccination strategies in multiple myeloma. Am J Hematol. 2023;98(Suppl 2):S46–S62. doi:10.1002/ajh.26766
   PubMedGoogle Scholar
• Park H, Youk J, Kim HR, et al. Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol. 2017;106(6):801–810. doi:10.1007/s12185-017-2313-2
   PubMed Web of Science ®Google Scholar
• Zheng G, Guan F, Han X, et al. Efficacy of intermittent, oral famciclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Front Oncol. 2022;12:843032. doi:10.3389/fonc.2022.843032
   PubMed Web of Science ®Google Scholar
• Ghate M, Deshpande S, Tripathy S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13(1):e1–e8. doi:10.1016/j.ijid.2008.03.029
   PubMedGoogle Scholar
• Dosani T, Mailankody S, Korde N, et al. Host-related immunodeficiency in the development of multiple myeloma. Leuk Lymphoma. 2018;59(5):1127–1132. doi:10.1080/10428194.2017.1361026
   PubMed Web of Science ®Google Scholar
• Suen H, Brown R, Yang S, et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia. 2016;30(8):1716–1724. doi:10.1038/leu.2016.84
   PubMed Web of Science ®Google Scholar
• Trotta R, Dal Col J, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181(6):3784–3792. doi:10.4049/jimmunol.181.6.3784
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–477. doi:10.1001/jama.2022.0003
   PubMed Web of Science ®Google Scholar
• Nahi H, Chrobok M, Gran C, et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One. 2019;14(2):e0211927. doi:10.1371/journal.pone.0211927
   PubMed Web of Science ®Google Scholar
• Yarlagadda L, Gundarlapalli S, Parikh R, et al. Salvage autologous stem cell transplantation in daratumumab-refractory multiple myeloma. Cancers. 2021;13(16):4019. doi:10.3390/cancers13164019
   PubMed Web of Science ®Google Scholar
• John L, Sauer S, Hegenbart U, et al. Idecabtagene vicleucel is well tolerated and effective in relapsed/refractory myeloma patients with prior allogeneic stem cell transplantation. Transplant Cell Ther. 2023;29(10):609.e1–609.e6. doi:10.1016/j.jtct.2023.06.010
   PubMedGoogle Scholar
• Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR. Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma. J Clin Oncol. 2023;41(10):1949–1951. doi:10.1200/JCO.22.02197
   PubMed Web of Science ®Google Scholar
• Teh BW, Teng JC, Urbancic K, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28–e31. doi:10.3324/haematol.2014.114025
   PubMed Web of Science ®Google Scholar
• Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer. 2016;67:21–37. doi:10.1016/j.ejca.2016.07.025
   PubMed Web of Science ®Google Scholar
• Brioli A, Klaus M, Sayer H, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98(3):713–722. doi:10.1007/s00277-019-03621-1
   PubMed Web of Science ®Google Scholar
• Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 2006;107(9):3575–3583. doi:10.1182/blood-2005-05-2118
   PubMed Web of Science ®Google Scholar
• Jones JO, Arvin AM. Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J Virol. 2006;80(11):5113–5124. doi:10.1128/JVI.01956-05
   PubMed Web of Science ®Google Scholar
• Berges C, Haberstock H, Fuchs D, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008;124(2):234–246. doi:10.1111/j.1365-2567.2007.02761.x
   PubMed Web of Science ®Google Scholar
• Heider U, Rademacher J, Kaiser M, Kleeberg L, von Metzler I, Sezer O. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk. 2010;10(2):134–137. doi:10.3816/CLML.2010.n.019
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma. 2008;8(4):237–240. doi:10.3816/CLM.2008.n.031
   PubMedGoogle Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784–4790. doi:10.1200/JCO.2007.14.9641
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–1266. doi:10.3324/haematol.2014.117176
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Michielin O, Cervera C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect. 2018;2(Suppl 2):S95–S107. doi:10.1016/j.cmi.2018.01.030
   Google Scholar
• Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115(1):229–232. doi:10.1002/cncr.24006
   PubMed Web of Science ®Google Scholar
• Swaika A, Paulus A, Miller KC, et al. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012;10(4):155–159. doi:10.1016/j.suponc.2011.10.006
   PubMedGoogle Scholar
• Fukushima T, Sato T, Nakamura T, et al. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res. 2012;32(12):5437–5440.
   PubMed Web of Science ®Google Scholar
• Ying T, Aijun L. Chen Wenming Clinical observation of the use of bortezomib in the prevention of herpes zoster in patients with multiple myeloma using valacilovir. Chin J Clin Physic. 2013;7(12):5634–5636.
   Google Scholar
• Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter Phase 1/2 study. Blood. 2006;108(7):2165–2172. doi:10.1182/blood-2006-04-019778
   PubMed Web of Science ®Google Scholar
• Pour L, Adam Z, Buresova L, et al. Varicella-zoster virus prophylaxis with low-dose Acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9(2):151–153. doi:10.3816/CLM.2009.n.036
   PubMedGoogle Scholar
• Minarik J, Pika T, Bacovsky J, Langova K, Scudla V. Low-dose Acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol. 2012;159(1):111–113. doi:10.1111/j.1365-2141.2012.09233.x
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Do YR, Bae SH, Yang DH, Lee JJ. Low-dose Acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol. 2011;41(3):353–357. doi:10.1093/jjco/hyq194
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K, et al. Long-term ultra-low-dose Acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2008;83(6):472–476. doi:10.1002/ajh.21152
   PubMed Web of Science ®Google Scholar
• Abbasov E, Metzner B, Müller TH, et al. Herpes zoster prophylaxis with low-dose Acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation. Eur J Haematol. 2022;109(3):298–304. doi:10.1111/ejh.13810
   PubMed Web of Science ®Google Scholar
• Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10135):2116–2127. doi:10.1016/S0140-6736(18)30631-7
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a Phase 3, randomised, clinical trial and post-hoc efficacy analysis [published correction appears in Lancet Infect Dis. 2020 Jan; 20(1):e1]. Lancet Infect Dis. 2019;19(9):988–1000. doi:10.1016/S1473-3099(19)30163-X
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, El Idrissi M, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Hum Vaccin Immunother. 2021;17(11):4144–4154. doi:10.1080/21645515.2021.1953346
   PubMed Web of Science ®Google Scholar
• Teh BW, Harrison SJ, Allison CC, et al. Predicting risk of infection in patients with newly diagnosed multiple myeloma: utility of immune profiling. Front Immunol. 2017;8:1247. doi:10.3389/fimmu.2017.01247
   PubMed Web of Science ®Google Scholar
• Dumontet C, Hulin C, Dimopoulos MA, et al. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018;32(6):1404–1413. doi:10.1038/s41375-018-0133-x
   PubMed Web of Science ®Google Scholar
• Mai EK, Huhn S, Miah K, et al. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer J. 2023;13(1):1. doi:10.1038/s41408-022-00772-9
   PubMed Web of Science ®Google Scholar
• Mai EK, Hielscher T, Bertsch U, et al. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients. Leukemia. 2024;38(3):640–647. doi:10.1038/s41375-023-02105-6
   PubMedGoogle Scholar